Cisplatin/carboplatin cross-resistance in ovarian cancer
Open accessThe DOI matches its Crossref record.
Abstract
Forty-six patients who were treated with cisplatin or carboplatin for ovarian cancer developed resistant disease (no change in measurable disease or progressive disease) and 'crossed over' to the other platinum compound. Three patients (6.5%) responded to this second treatment but these patients had no survival advantage compared to the non-responders. One responder had progressive disease on cisplatin before crossing over to carboplatin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Systems biology of cisplatin resistance: past, present and future
Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.428 · Cited by 782
New Cisplatin Analogues in Development: A Review
Weiss, R. B., & Christian, M. C. (1993) · Drugs · doi:10.2165/00003495-199346030-00003 · Cited by 404
Gore, M. E., Fryatt, I., Wiltshaw, E., & Dawson, T. (1990) · Gynecologic Oncology · doi:10.1016/0090-8258(90)90174-j · Cited by 381
Self-citationHyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
Helm, C. W., Richard, S. D., Pan, J., Bartlett, D., Goodman, M. D., Hoefer, R., Lentz, S. S., Levine, E. A., Loggie, B. W., Metzinger, D. S., et al. (2010) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181c50cde · Cited by 302
Barr, M. P., Gray, S. G., Hoffmann, A. C., Hilger, R. A., Thomale, J., O’Flaherty, J. D., Fennell, D. A., Richard, D., O’Leary, J. J., & O’Byrne, K. J. (2020) · PLOS ONE · doi:10.1371/journal.pone.0233739 · Cited by 269
Barr, M. P., Gray, S. G., Hoffmann, A. C., Hilger, R. A., Thomale, J., O’Flaherty, J. D., Fennell, D. A., Richard, D., O’Leary, J. J., & O’Byrne, K. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054193 · Cited by 19
“In this respect, it is noteworthy that cisplatin-resistant tumours are fully cross-resistant to the platinum analogue carboplatin [17,18].”
Background
Metadata
- Authors
- Gore, M., Fryatt, I., Wiltshaw, E., Dawson, T., Robinson, B., & Calvert, A.
- Venue
- British Journal of Cancer
- Published
- 1989-11
- Volume
- 60
- Issue
- 5
- Pages
- 767-769
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2056359433
- Cited by
- 116
- References
- 0
- FWCI
- 7.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.